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A national survey was sent to all appropriate Veterans Health Administration (VA) medical facilities asking
about the ability to test for Staphylococcus aureus with reduced susceptibility to vancomycin (SARV)
(MICs >4  µg/mL). For those with this ability, a request was made for the number of patients having SARV
isolated during a 1-year period. Nineteen patients from eight sites across the country had isolation of
SARV. Of these, MicroScan (Dade Behring, Inc, MicroScan Division, West Sacramento, CA) technology
was used for 17 patients, Vitek (Hazelwood, MO) was used for 1 of the remaining 2 patients, and E-test
(AB Biodisk North America, Inc, Piscataway, NJ) for the other. All patients with this organism had microbi-
ology testing done onsite in the reporting VA facility’s College of American Pathologists-approved labora-
tory. For comparison, similar data were obtained for a 1-year period 2 years prior to the current survey;
seven patients from four sites were verified to have a SARV. Between the two survey periods the reported
cases of SARV increased 170%, indicating a need for continued surveillance and potentially a need to ini-
tiate a collection of isolates for further analysis.
merging microbial resistance is a substantial threat to
health (1). With the discovery of methicillin-resistant Sta-
phylococcus aureus (MRSA) that also had intermediate resis-
tance to vancomycin in 1996 in Japan, more intense scrutiny
has been given to identifying resistance and reduced suscepti-
bility in staphylococcal species (2-4). Even before the Japa-
nese isolate was identified, in vitro evidence that vancomycin-
resistant enterococci (VRE) could transfer resistance to sta-
phylococci led to concern for spread of vancomycin resistance
to the staphylococci (5-7).
In 1995, the Centers for Disease Control and Prevention
(CDC) recommended microbiology laboratories be vigilant for
the occurrence of vancomycin resistance in staphylococci
along with confirmatory testing and reporting such resistance
to public health authorities (5). Further, recommendations in
1997 called for vigilance for reduced susceptibility to vanco-
mycin (MIC >4 µg/mL) rather than just vancomycin resistance
(MIC >32  µg/mL) (8,9). These recommendations included
awareness of the significance of isolates with reduced suscep-
tibility, confirmatory testing of suspect isolates, retesting sta-
phylococci isolated from patients who have failed to respond
to vancomycin therapy, and notification of public health
authorities. The National Committee for Clinical Laboratory
Standards (NCCLS) has set S. aureus breakpoints for vanco-
mycin at <4  µg/mL is interpreted as susceptible, 8-16  µg/mL
is intermediate and >32  µg/mL is resistant (10). Despite the
fact that an MIC = 4  µg/mL is defined as susceptible by
NCCLS standards, it is considered to be at the borderline of
resistance (11). In particular, S. aureus strains that are methi-
cillin or oxacillin resistant and that have an MIC to vancomy-
cin of $4  µg/mL should be suspected for decreased
susceptibility to vancomycin and should be considered for
additional testing strategies because of the possible subpopula-
tion heterogeneity of S. aureus isolates with these MIC results
(11,12).
Recent studies from CDC indicate that proper identifica-
tion of antibiotic resistance may be difficult despite adequate
capacity for testing (13). A selected survey of laboratories par-
ticipating in CDC surveillance (Active Bacterial Core Surveil-
lance and Emerging Infections Programs Network) indicates
that these issues may occur despite active participation in CDC
activities (13). A more recent study involving the worldwide
WHONET users suggested that these difficulties in identifica-
tion of antibiotic resistance might be even greater (14). These
studies indicate that real-world application of recommended
standards into typical day-to-day functioning does not mimic
the functioning and results seen in tightly controlled study sit-
uations.
1 A portion of this material was presented at the 11th Annual Scientific
Meeting of the Society for Healthcare Epidemiology of America in Tor-
onto, Ontario, Canada (Abstract #49), April 2001. 
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Through its annual survey for federal fiscal year (FY) 1999
(October 1, 1998 through September 30, 1999), the Infectious
Diseases Program Office of the United States Department of
Veterans Affairs (VA) undertook a national assessment of the
VA health-care system surveillance for SARV. In addition to
identifying cases with vancomycin (glycopeptide)-resistant or
-intermediate isolates, we sought to identify those cases with
the potential for decreased susceptibility to vancomycin.
Therefore, we have chosen to use the designation of SARV to
encompass all of these. During FY 1999, the VA health-care
system served a population of >3.6 million persons in its 172
medical centers and >600 outpatient clinics; it had approxi-
mately 600,000 inpatient discharges and >35 million outpa-
tient visits during that same period. 
Materials and Methods
Annually since 1990, the Infectious Diseases Program
Office for VA Central Office has distributed an Infectious Dis-
eases/Infection Control survey requesting data on several top-
ics to all VA medical center reporting sites across the country.
The process for the survey begins with the distribution of the
annual survey instrument (questionnaire) to each VA medical
center reporting site; this is delivered to the administrator
responsible for the facility. Subsequently, a 2-week period is
established for receipt of responses to the survey. Responses
are made by electronic entry into a central database by each
site. Each site notes a point of contact for subsequent data ver-
ification. After the 2-week period, the ability to access the
database for entry is closed to the medical center reporting
sites.
Administrative review by the Infectious Diseases Program
Office identifies medical centers that have omitted data. The
point of contact is queried (either by telephone or e-mail) as to
the nature of the omission. Concomitant with the review of
data for omission, a preliminary analysis of the submitted data
is undertaken to assess for accuracy of other reported data and
consistency of reporting with previously submitted data from
the medical center. There are several questions in the Infec-
tious Diseases/Infection Control  annual survey that serve as
controls for analysis. If there is concern that the submitted data
may be inaccurate, the point of contact for the site is also que-
ried to verify these data.
Beginning in 1998 (for FY 1997 data), the survey included
two questions regarding SARV. The following questions were
asked, 1) Does your facility do or obtain testing to identify
reduced susceptibility to vancomycin (MIC >4  µg/mL) for
Staphylococcus aureus? Yes or no? 2) If yes, report the number
of patients (not cultures) with Staphylococcus aureus with
reduced susceptibility to vancomycin (MIC >4  µg/mL). 
Any site reporting presence of a patient with SARV was
contacted by the Infectious Diseases Program Office to verify
accuracy of the report for both FY 1997 and 1999 data. During
the contact by the Infectious Diseases Program Office (Janu-
ary 2001) for FY 1999 data, additional information was
requested from those sites that reported and verified patients
with SARV. This additional information included verification
that the isolate was indeed S. aureus, identification of the sus-
ceptibility testing methods, source of the specimen, inpatient
or outpatient status at the time of specimen acquisition, and
MIC to vancomycin. Query was also made regarding confir-
matory testing of vancomycin susceptibility of the patient iso-
late, susceptibility testing to other antimicrobial agents, and
current availability of the isolate. 
Results
For FY 1997, there was 100% response to the survey
instrument (146 reporting sites), although not all questions
were completed. Initially 11 sites reported 284 patients with
SARV. After contact and verification of the survey results by
the Infectious Diseases Program Office with these sites, seven
patients were reported to have SARV from four of the sites.
Rationale for discounting initially reported cases after verifica-
tion included misinterpretation of the question to be requesting
information on VRE or misinterpretation of the question to
mean MRSA.
For FY 1999, there was 99% response to the survey instru-
ment (142 of 143 reporting sites), though not all questions
were initially completed. With regard to the ability of the
reporting facility to do or obtain testing to identify SARV, 142
reporting sites answered this question, with 123 (86%) of the
sites responding “yes.” Of the 123 sites reporting yes, initially
13 sites reported 195 patients with SARV. After contact and
verification by the Infectious Diseases Program Office, the
number of verified, reported cases was revised to eight sites
reporting 19 patients with SARV. Reasons for change of
reported numbers to verified numbers included misinterpreta-
tion of the question to mean MRSA as well as one isolate with
a difficult determination by the original MIC method used
(reporting an MIC >16  µg/mL) but with confirmatory testing
defining an MIC = 1.5  µg/mL. Microbiology testing was
noted to be done onsite in a CAP-approved laboratory for all
reported and verified cases. 
The specimen sources for these isolates were five from tis-
sue or wounds, five from a urinary source, four from sputum,
two from abdominal or peritoneal sources, and one each from
blood, eye, and synovial fluid. Initial susceptibility testing
showed 17 used MicroScan technologies (Dade Behring, Inc,
MicroScan Division, West Sacramento, CA) and one each of
bioMerieux Vitek (Hazelwood, MO), and E-test (AB Biodisk
North America, Inc, Piscataway, NJ) (Table 1). Confirmatory
testing was done on only 2 of the 19 reported cases, using E-
test and MicroScan technology (Table 1). One isolate was sent
to CDC for confirmation. However, as noted above, confirma-
tory testing had also been done on at least one occasion to
refute presence of SARV. Sixteen of the isolates were reported
to have an MIC = 4  µg/mL, one was reported to have an MIC
= 8  µg/mL (noted to be an intermediate sensitivity interpreta-
tion), one was reported at >16  µg/mL, while one was reported
at >32 µg/mL; these last two isolates were interpreted as being
resistant. Six of these specimens were obtained from patientsRESEARCH
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during an outpatient encounter, while seven were obtained
while patients were on inpatient status, and five were from
patients in a nursing home. Only one of the 19 case isolates
had been stored and is available for further analysis.
Reported susceptibility testing to other antimicrobial
agents are noted in Tables 2 and 3 where data were available;
not all isolates had susceptibility testing done against all anti-
microbial agents reported. Beta-lactamase activity was present
for 14 of the 16 isolates. For penicillin-type antibiotics, 12 of
the 19 isolates had oxacillin resistance. There was also a rela-
tively high degree of resistance to the cephalosporins tested
(data not shown) and six of eight isolates were resistant to imi-
penem. Antibiotic susceptibility testing against other agents
used to treat gram-positive infections showed varying degrees
of resistance, with 4 of 15 isolates resistant to rifampin, 14 of
18 resistant to erythromycin, 12 of 17 resistant to clindamycin,
4 of 17 resistant to tetracycline, only 1 of the 19 isolates resis-
tant to trimethoprim/sulfamethoxazole, and none of 4 isolates
resistant to chloramphenicol. For the quinolones and other
agents, 5 of 16 were resistant to ciprofloxacin, 4 of 5 were
resistant to levafloxacin, 4 of 7 were resistant to ofloxacin, and
3 of 16 were resistant to gentamicin. 
Discussion
In this survey, patients were reported to have SARV in the
VA system for both FYs 1997 and 1999. Two VA sites
reported cases of SARV in both surveys. Comparison of the
two surveys indicates an increase of 170% in the number of
cases reported in 1999 compared with 1997. This finding is in
contradistinction to information reported by MRL Pharmaceu-
tical Services, where none of 3,797 S. aureus isolates had
reduced susceptibility to vancomycin in 1999 (15). Even
Table 1. Information from reported isolates of Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans 
Health Administration medical facilities, FYa 1999
Case
Inpt/Outpt/
NHb Specimen Methodc (Instrumentation/panel)
MIC/
susceptibilityd
Confirmation 
of susceptibility
Confirmation 
methodology
1 Outpt Ear tissue MicroScan Walkaway version 22.01/Gram 
Pos Combo Panel 10
> 16  µg/mL/R Yes MicroScan 
Walkaway
2 Inpt/SICUe ABDf and 
VPg shunt
MicroScan Walkaway version 22.06/Pos Combo 12 = 4  µg/mL/S No --
3 Inpt Sputum MicroScan Walkaway version 22.26/Pos Combo 14 = 4  µg/mL/S No --
4 Outpt Urine MicroScan Walkaway version 22.06/Pos Combo 12 = 4  µg/mL/S No --
5 Outpt Leg MicroScan Walkaway/Pos Combo Panel 10 = 4  µg/mL/S No --
6 Outpt Eye MicroScan Walkaway/Pos Combo Panel 10 = 8  µg/mL/(I) No --
7 Inpt Peritoneal MicroScan Walkaway/Pos Combo Panel 10 = 4  µg/mL/S No --
8 Inpt Urine MicroScan Walkaway/Pos Combo Panel 10 = 4  µg/mL/S No --
9 Outpt Wound MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
10 NH Sputum MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
11 NH Sputum MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
12 NH Urine MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
13 NH Urine MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
14 NH Wound MicroScan AutoScan/Pos Combo 11 = 4  µg/mL/S No --
15 Inpt Foot wound E-test; VCNh screen plate = 4  µg/mL/S Yes Sent to CDCi; E-test
16 Outpt Synovial 
fluid
MicroScan Walkaway/Gram Pos Combo Panel 10 = 4  µg/mL/S No --
17 Inpt/MICUj Sputum MicroScan Walkaway/Gram Pos Combo Panel 10 = 4  µg/mL/S No --
18 Inpt/ICUk Blood MicroScan AutoScan version 22.01/Pos Combo Panel 10 = 4  µg/mL/S No --
19 Inpt/MICU Urine BioMerieux Vitek VTK-R version 07.01/GPS-102 > 32  µg/mL/R Unable to 
determine
--
aFY=Federal fiscal year.
bInpt=inpatient; Outpt=outpatient; NH=nursing home.
c bioMerieux Vitek (Hazelwood, MO), E-test (AB Biodisk North America, Inc., Piscataway, NJ), MicroScan (Dade Behring Inc., MicroScan Division, West Sacramento, CA). Where 
data were available, software version of technology provided. All MicroScan methods used conventional 24-hour incubation susceptibility panels. 
d Susceptibility interpretation at the reporting site (S=sensitive, I=intermediate, R=resistant).
e SICU=surgical intensive care unit.
fABD=abdominal.
gVP=Ventriculo-peritoneal.
hVCN=vancomycin.
iCDC=Centers for Diseases Control and Prevention.
jMICU=medical intensive care unit.
kICU=intensive care unit.Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 405
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though different methods of data accrual were used, both sur-
veys rely on NCCLS-based susceptibility criteria (10). Despite
the fact that presence of SARV appears to be a low-incidence
occurrence at this time, the reason for different occurrences of
SARV between the VA and this other national data set (15) is
not readily apparent from the data present. The difference of
findings, even though both use NCCLS-based susceptibility
criteria, may be based on the fact that the MRL study used one
consistent microbroth dilution method for susceptibility test-
ing whereas our population-based reporting survey encom-
passes numerous susceptibility testing methods (MicroScan,
Vitek, E-test, screening plates) more analogous to real-world
application of technologies. Tenover et al. (11) demonstrated
different methods of susceptibility testing (e.g., MicroScan
Rapid panels and disk diffusion) have been shown to be unreli-
able in detecting S. aureus strains with reduced susceptibility
of vancomycin; none of the VA laboratories reporting SARV
used those methods considered to be unreliable (Table 1).
Sampling size may be a factor, as we do not have the total
number of isolates tested nationwide in the VA, but the total
number likely exceeds the number of isolates in the MRL
study. Different populations sampled or the recent CDC stud-
ies indicating difficulty in delimiting antibiotic resistance
(13,14) might all contribute to this difference as well.
Because of limitations in our survey methods, we are
unable to supply information on the total number of S. aureus
isolates (or persons with S. aureus isolated) within the VA sys-
tem nationwide, from which to determine prevalence estimates
for comparative purposes to other studies (16,17). Data from
Wilcox et al. and Aucken et al. indicate that about 15% of iso-
lates in the United Kingdom had a vancomycin MIC of 4  µg/
mL on initial testing (16,17). These two reports also indicate a
low prevalence of vancomycin (glycopeptide)-intermediate or
-resistant isolates upon confirmation. The reports also lend
support to the finding that susceptibility testing of S. aureus to
vancomycin by disk diffusion, which is commonly used in the
United Kingdom, is not as reliable as other methods of testing
for reduced susceptibility of S. aureus to vancomycin (11).
For each of the 2 years surveyed, more sites initially
reported patients with SARV than were present after verifica-
tion by the Infectious Diseases Program Office. The most
common reason noted for the inaccurately reported data was
Table 2. Susceptibility to selected gram-positive agents of isolates of reported Staphylococcus aureus with reduced
susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FY 1999a
Case
Beta-lac-
tamase
MIC/sensitivity status
oxacillin imipenem rifampin TMP/SMX erythromycin TCN clindamycin chloramphenicol
1 negative  /R  /S  /R  /S  /R
2 positive <0.5  µg/mL <4 µg/mL <1 µg/mL <2 µg/mL =0.5 µg/mL <2 µg/mL <0.25 µg/mL
3 positive >2  µg/mL >8 µg/mL/R <1 µg/mL <2 µg/mL >4 µg/mL/R <2 µg/mL >2 µg/mL/R
4 positive >4  µg/mL >8 µg/mL/R <1 µg/mL <2 µg/mL >4 µg/mL/R <2 µg/mL >2 µg/mL/R
5 positive <0.5    µg/mL/S >8 µg/mL/R >2 µg/mL/R <2/38 µg/mL/S >8 µg/mL/R >2 µg/mL/R
6 positive >2    µg/mL/R 2 µg/mL/R >1 µg/mL/S <2/38 µg/mL/S >4 µg.mL/R <2 µg/mL/S 8 µg/mL/S
7 positive >2    µg/mL/R >8 µg/mL/R >2 µg/mL/R >2/38 µg/mL/R >4 µg/mL/R >8 µg/mL/R 16 µg/mL/I
8 positive >2    µg/mL/R >8 µg/mL/R >1 µg/mL/S <2/38 µg/mL/S >4 µg/mL/R <2 µg/mL/S >2 µg/mL/R 16 µg/mL/I
9 positive >2 µg/mL/R <1 µg/mL/S <2 µg/mL/S >4 µg/mL/R <2 µg/mL/S >2 µ/mL/R
10 negative <0.5 µg/mL/S <1  µg/mL/S <2 µg/mL/S <0.25 µg/mL/S <2 µg/mL/S =0.5 µg/mL/S
11 positive <0.5 µg/mL/S <1 µg/mL/S <2 µg/mL/S >4 µg/mL/R <2 µg/mL/S <0.25 µg/mL/S
12 positive >2 µg/mL/R <1 µg/mL/S <2 µg/mL/S >4 µg/mL/R <2 µg/mL/S >2 µ/mL/R
13 positive <0.5 µg/mL/S <1 µg/mL/S <2 µg/mL/S >4 µg/mL/R >8 µg/mL/R >2 µg/mL/R
14 positive >2 µg/mL/R >2 µg/mL/R <2 µg/mL/S >4 µg/mL/R <2 µg/mL/S >2 µg/mL/R
15  /R <2 µg/mL/S  /R <2 µg/mL/S <2 µg/mL/S 8 µg/mL/S
16 1 µg/mL/S <2/38 µg/mL/S 0.5 µg/mL/S >2 µg/mL/R
17 >4 µg/mL/R <2/38 µg/mL/S >4 µg/mL/R >2 µg/mL/R
18 positive <0.05 µg/mL <4 µg/mL <1 µg/mL <2 µg/mL <0.25 µg/mL <2 µg/mL 0.5 µg/mL
19 positive >8 µg/mL/R >4 µg/mL/R <16 µg/mL/S >8 µg/mL/R >16 µg/mL/R >8 µg/mL/R
Totalb 14/
16=pos
12/19 =R 6/8=R 4/15=R 1/19=R 14/18=R 4/17=R 12/17=R  0/4=R
aFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria; TMP/SMX=trimethoprin/sulfamethoxazole; 
TCN=tetracycline
bThe authors took the liberty of placing interpretation on some reported MIC values that did not have an interpretation of S, I, or R on information provided 
from the facility.RESEARCH
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misinterpretation of the question to mean MRSA, indicating
that despite a simply worded question giving specific defini-
tions, data validation is important. Validation is especially
important for low-incidence diseases, for which a few misre-
ported cases may significantly alter the final outcome.
Despite CDC recommendations on confirmatory testing of
suspect isolates, repeat susceptibility testing is not being per-
formed consistently for all isolates. If confirmatory testing is
being performed, it is not being recorded; therefore, it is not
reported in this retrospective review. NCCLS does not indicate
the need for repeat testing (10). Further, from the survey we
were not able to determine if confirmatory testing of the iso-
late to indeed be S. aureus was occurring. However, each site
did note that it was confident of the organism identification.
Perhaps of greater importance is the recognition that despite
CDC recommendations for confirmatory testing to be done for
isolates of staphylococci with MICs >4  µg/mL to vancomy-
cin, the Infectious Diseases Program Office was informed by
several of the sites reporting SARV that an MIC of 4  µg/mL
was interpreted as susceptible by NCCLS criteria (10); there-
fore, it was not necessary to confirm this result. The lack of
confirmatory testing indicates poor recognition for the signifi-
cance of S. aureus having the potential for reduced susceptibil-
ity to vancomycin. Also, only one site (of eight sites in FY
1999) reported contacting a public health authority about a
SARV isolate (i.e., sent to CDC for confirmatory testing),
again indicating a lack of recognition of important Public
Health Service recommendations (8). No other reports indicate
the extent of adherence to such national recommendations
about SARV. Even though this lack of recognition and report-
ing is not the same as the capacity to detect antimicrobial resis-
tance, it is analogous to CDC findings that confirmation of
susceptibility for suspected SARV was as low as 39% (13).
Upon review of other antimicrobial susceptibilities of the
19 SARV cases from FY 1999, a high degree of resistance to
other agents was found; however, a third of isolates were noted
to be susceptible to oxacillin or methicillin. Therefore, not all
reported cases of SARV were also MRSA. Non-aureus staphy-
lococcal species were not reviewed in this survey. Some
reports indicate that coagulase-negative staphylococci also
have reduced susceptibility to vancomycin (18).
Given the limitation to two basic questions imposed by the
Infectious Diseases/Infection Control  annual survey methods,
the full extent and characterization of S. aureus with reduced
susceptibility to vancomycin in the VA cannot be accurately
assessed. However, this method has indicated that SARV
exists in the VA health-care system, the occurrence of which
has increased between the 2 years reviewed. This study also
Table 3. Reported susceptibility to quinolones and other agents of reported isolates of Staphylococcus aureus with reduced susceptibility to van-
comycin from United States Veterans Health Administration medical facilities, FY 1999a
Case
MIC/sensitivity status
ciprofloxacin levofloxacin ofloxacin norfloxacin gentamicin furodantin
1 / S
2< 1   µg/mL <4 µg/mL <1 µg/mL <32 µg/mL
3> 2   µg/mL/R >4 µg/mL/R >8 µg/mL <1 µg/mL <32 µg/mL
4> 2   µg/mL/R >8 µg/mL <1 µg/mL <32 µg/mL
5< 1 µg/mL/S 4 µg/mL/I <1 µg/mL/S
6> 2   µg/mL/R >4 µg/mL/R 8 µg/mL/I
7> 2   µg/mL/R >4 µg/mL/R >8 µg/mL/R
8> 2   µg/mL/R >4 µg/mL/R >8 µg/mL/R
9> 2   µg/mL/R >4 µg/mL/R <1 µg/mL/S <32 µg/mL
10 =2 µg/mL/I <2 µg/mL/S <1 µg/mL/S =64 µg/mL
11 >2 µg/mL/R >4 µg/mL/R <1 µg/mL/S <32 µg/mL
12 >2 µg/mL/R >4 µg/mL/R <1 µg/mL/S <32 µg/mL/S
13 >2 µg/mL/R >4 µg/mL/R <1 µg/mL/S <32 µg/mL/S
14 <1 µg/mL/S <2 µg/mL/S <1 µg/mL/S <32 µg/mL
15  /R
16
17
18 <1 µg/mL <1 µg/mL
19 <0.5 µg/mL/S <1 µg/mL/S <2 µg/mL/S
Total 9/16=R 4/5=R 4/7=R 3/16=R
aFY=Federal fiscal year; S=susceptible, I=intermediate and R=resistant based on laboratory interpretative criteria.Emerging Infectious Diseases  •  Vol. 8, No. 4, April 2002 407
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identified the importance of data validation as evidenced by
misinterpretation of clearly stated and defined questions. With
the presence of this organism and its apparent increase in
occurrence, continued surveillance is indicated. A more thor-
ough analysis of the extent and characteristics of this organism
in the VA system would be beneficial to both VA and public
health in general; this analysis might include patient character-
istics, antibiotic use in patients before acquisition of SARV,
and collection and storage of isolates for further laboratory
analysis. Along with further characterization of the epidemiol-
ogy of this organism, increasing awareness as to the signifi-
cance of SARV is indicated.
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